Vera Malkovska, MD, is director of Hematology at MedStar Washington Hospital Center. In addition, she is an associate research professor of Pediatrics, George Washington University, and a senior investigator, Children's Research Institute, Children's National Medical Center, Washington, D.C.
Her research has been published in Leukemia & Lymphoma, Critical Care Medicine,Cancer Investigation and other peer-reviewed journals. In addition, she has written chapters and review articles on specialized topics, including tumor immunotherapy, hematologic malignancies and treatment of lymphomas and leukemias. She is board certified in Internal Medicine and Hematology and is a member of the American Society of Hematology and the American Society of Clinical Oncology.
Dr. Malkovska received her medical degree from Charles University Medical School in Prague, Czechoslovakia, where she also completed a residency in Medicine/Hematology/Gastroenterology. She completed an additional residency in Surgery/Medicine/Nephrology and a fellowship in Hematology at the Institute of Clinical and Experimental Medicine, Prague. After moving to the United Kingdom, she was a senior house officer (resident) in Pathology and Medicine, a registrar in Hematology and Medicine, and completed a fellowship as a senior registrar (fellow) in Hematology at Northwick Park Hospital, Harrow, U.K.
Dr. Malkovska's research interests include
- Disorders of the blood and blood-forming organs
- Hematological malignancy
- Multiple myeloma
Obesity in adult lymphoma survivors
Although survivors of lymphoma are living longer, their mortality is higher than that of the general population, and survivors of childhood leukemia and lymphoma appear to have increased prevalence of obesity. In this study, published in Leukemia & Lymphoma (2012;53:569-74), Dr. Malkovska and colleagues studied weight change in adults who had been treated for lymphoma.
Primary lymphoma of bone
In this study, published in Leukemia & Lymphoma (2008;49:2125-32), Dr. Malkovska and colleagues investigated factors influencing survival in patients with primary bone lymphoma. The authors found a statistically significant difference in overall survival with the use of combined chemotherapy (with or without rituximab) and radiation compared with either therapy alone.
- Research Areas
- Primary Care/Pediatrics